Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Trial to Investigate the Efficacy and Safety of Weekly Intra-articular (i.a.) Injections of 10, 30, and 100 µg of AS902330 for Three Consecutive Weeks in Patients With Acute Cartilage Injury of the Knee
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Sprifermin (Primary)
- Indications Cartilage disorders
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 06 Oct 2014 New trial record